PRO17080173

About this trial

Last updated 7 years ago

Study ID

PRO17080173

Status

Completed

Type

Interventional

Phase

N/A

Placebo

Accepting

7 to 17 Years

All

Trial Timing

Ended 7 years ago

This study will evaluate the perceptions of the effects of two anxiolytic medications commonly used during dental treatment in patients weighing 40 kilograms or more.

Inclusion Criteria

1. Weigh 40 kilograms or more.

2. 2/4 or 3/4 Frankl Behavioral Rating at their evaluation appointment.

3. Dental treatment that requires two sedation appointments. Dental treatment that requires sedation includes: fillings, crowns, pulpotomies and/or extractions.

4. Between the ages of 7-17 years old.

Exclusion Criteria

1. Patients taking any of the following medications will be excluded from the study: Atripia, cimetidine, diltiazem, erythromycin, fluconazole, grapefruit juice, isoniazid, itraconazole, ketoconazole, nefazodone, rifampicin, ritonavir, fusidic acid, idelalisisb, methadone, olanzapine, thalidomide and/or troleandomycin.

2. Pregnant patients will be excluded.

3. Patients that have HIV-1 that is being treated with a protease inhibitor will be excluded.

4. Patients with a MTHFR mutation will be excluded.

5. Patients with acute narrow angle glaucoma will be excluded.

6. Patients that have had a previous adverse, paradoxical or allergic reaction to any benzodiazepines will be excluded from the study.

7. Patients unable to swallow medication in tablet form.

8. Patients that do not speak English as their primary language.

Comparison of Triazolam and Midazolam for Anxiolysis During Dental Treatment in the Pediatric Patient